For Healthcare Professionals Outside the US

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma

For patients with BRAF V600 mutation–positive advanced non-small cell lung cancer (NSCLC)

Tafinlar® (dabrafenib) + Mekinist® (trametinib) disease control rate

Across 2 phase 3 studies, more than 90% of patients treated with Tafinlar® (dabrafenib) + Mekinist® (trametinib) achieved disease control or better1,2

Disease control rate of Tafinlar® (dabrafenib) + Mekinist® (trametinib) vs. other treatments

  • The DCR in patients who received Tafinlar + Mekinist ranged from 91% to 92% vs 84% with Tafinlar monotherapy and 84% with vemurafenib monotherapy1,2

CR, complete response; DCR, disease control rate; PR, partial response; SD, stable disease.

References: 1. Robert C, Karaszewska B, Schachter J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib + trametinib in patients with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. Presented at: European Society for Medical Oncology; October 7-11, 2016; Copenhagen, Denmark. 2. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444-451.